AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

Merck

Investors are shunning these stocks now, but that will change.

3 Top Pharma Stocks to Buy Now

Brookfield Renewable Partners

Innovative Industrial Properties

You really can have it all with these stocks.

3 Great Dividend Stocks That Are Also Fantastic Growth Stocks

Alexion Pharma

AstraZeneca has announced its acquiring Alexion at a fairly substantial 45% premium. It's a mixed stock - cash offer. The synergies will cover most of the ~$900 million in annual dividend / interest costs with significant growth potential.

The Next Major Pharmaceutical Acquisition Is Here

AstraZeneca plc (LON: AZN) said on Saturday that it will buy Alexion Pharmaceuticals (NASDAQ: ALXN) for £29.50 billion. The acquisition marks the largest for the British pharmaceutical giant in history.

AstraZeneca to acquire Alexion Pharmaceuticals for £29.50 billion

At $39 billion, AstraZeneca is low-balling its bid for Alexion -- maker of Soliris, a drug that sells for $678,302 a year

AstraZeneca To Pay $39B For Alexion — 14% Off Its All-Time High

Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion for $39 billion.

Covid-19 vaccine developer AstraZeneca agrees to buy rare disease firm Alexion for $39 billion

Alexion shareholders will receive a big premium in a combination of cash and AstraZeneca stock.

AstraZeneca to Buy Alexion Pharmaceuticals for $39 Billion

AstraZeneca plc (NASDAQ: AZN)has announced it will buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a Boston-based drugmaker, for $39 billion. What Happened: British pharmaceutical company AstraZeneca and Boston-based Alexion said this morning that their boards unanimously approved the deal.

AstraZeneca To Buy Rare-Disease Specialist Drugmaker Alexion For $39 Billion

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals in a $39 billion deal,  a move intended to boost AstraZeneca's immunology research and combine the company's delivery pipelines.  "Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology," said Pascal Soriot, chief executive of AstraZeneca, in a joint statement. 

AstraZeneca is acquiring Alexion Pharmaceuticals in a $39 billion pharmaceutical deal

AstraZeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday.

AstraZeneca to acquire Alexion in $39 billion deal

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--AstraZeneca to acquire Alexion, accelerating the Company's strategic and financial development

AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development

The drugmaker's efficacy results prompted confusion and consternation.

What's Behind AstraZeneca's COVID Vaccine Controversy?

Many officials worried about how fast Russia developed and approved the vaccine, launching it without completing the large-scale clinical trials needed to prove safety and efficacy.

AstraZeneca, Oxford To Create Combination Covid-19 Vaccine With Russia's Sputnik V

AstraZeneca, the British drugmaker working with the University of Oxford to develop a COVID-19 vaccine, plans to work with the developers of Russia's Sputnik V to explore a combined shot, it said. AstraZeneca "will soon begin exploring with Gamaleya Research Institute in Russia to understand whether two adenovirus-based vaccines can be successfully combined," the drugmaker said in a statement Friday, naming the developer of the Sputnik V vaccine, but not the specific shot.

AstraZeneca will work with the makers of Russia's Sputnik V vaccine to test a combined shot. This could make people more immune, and for a longer period of time, it said.

It comes after the developers of the Sputnik V Covid-19 vaccine approached AstraZeneca via Twitter late last month.

AstraZeneca to work on Covid vaccine combinations with Russia's Sputnik V developers

BioNTech SE

Moderna

Pfizer

The time to pick your horse in the vaccine race was months ago. These stocks were much cheaper before their trials started.

The Question to Ask About COVID-19 Vaccine Stocks

Proposals for two vaccines have not been granted yet as neither managed to submit adequate safety or efficacy data.

India Is Reportedly Seeking More Data On Oxford-AstraZeneca Vaccine Before Granting Emergency Authorization

It comes shortly after the Oxford-AstraZeneca vaccine candidate was found to be safe and effective in a peer-reviewed paper.

Oxford-AstraZeneca Covid vaccine to immunize the planet 'more effectively,' Lancet editor says

The latest update raises alarming questions that need answering.

3 New Red Flags for AstraZeneca's Coronavirus Vaccine

Johnson & Johnson

Don't expect just one or two winners in the coronavirus vaccine race. Be prepared for several.

After Moderna and Pfizer, Which Vaccine Makers May Cross the Finish Line Next?

AstraZeneca stock edged higher Tuesday after the company said its University of Oxford-partnered coronavirus vaccine prevented severe cases of Covid-19 in its final-phase test. The post AstraZeneca Says Vaccine Blocks Severe Covid-19; Shares Edge Higher appeared first on Investor's Business Daily.

AstraZeneca Says Vaccine Blocks Severe Covid-19; Shares Edge Higher

Biogen

GlaxoSmithKline

Sanofi

Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021. The post The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure appeared first on InvestorPlace.

The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure

The vaccine is cheaper and much easier to transport than Pfizer and Moderna's vaccines, which are 95% effective.

Questions Over Effectiveness Remain As AstraZeneca And Oxford Release Covid-19 Vaccine Trial Data

The British pharmaceutical giant submits its phase 3 data to a peer-reviewed journal, the first company to do so.

AstraZeneca COVID-19 Vaccine Achieves 70% Efficacy

AstraZeneca and the University of Oxford's experimental shot showed average efficacy of 70.4% in a pooled analysis of interim data from late-stage trials.

News for AstraZeneca Stock (AZN)